Barcha huquqlar himoyalangan.
2.74
0.00 (0.00%)
– Bempedoic Acid Receives Strongest Endorsement from AHA/ACC Multisociety Guideline for Patients with Statin Intolerance and in Primary and Secondary Prevention Patients with Severe Hypercholesterolemia –
Esperion Therapeutics' Q4 revenues surge 144% to $168.4M but EPS of 22 cents misses estimates. Shares fall as mixed results weigh on sentiment.
Esperion Therapeutics, Inc. (ESPR) Q4 2025 Earnings Call Transcript
Esperion Therapeutics (ESPR) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to a loss of $0.1 per share a year ago.
– FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –
Esperion to buy Corstasis for $75M in cash, adding FDA-approved Enbumyst nasal spray to its cardiovascular franchise. The deal is likely to be closed in Q2.
Esperion Therapeutics, Inc. (ESPR) M&A Call Transcript
There is no data to display
– Enbumyst ™ Is the First and Only FDA-Approved Nasal Spray Loop Diuretic for Edema Associated with Congestive Heart Failure, Expected to Leverage Esperion's Established Cardiovascular Commercial Infrastructure, Synergistically Expand Product Portfolio and Accelerate Double-Digit Revenue Growth –
ANN ARBOR, Mich. & HENDERSON, Nev.--(BUSINESS WIRE)-- #CHF--Esperion (NASDAQ: ESPR) and Corstasis Therapeutics Inc., a privately-held, commercial-stage biopharmaceutical company advancing innovative outpatient therapies for the treatment of edema associated with cardiovascular, and hepatic and renal disease, today announced they have entered into a definitive agreement for Esperion to acquire Corstasis. Under the terms of the agreement, Esperion will acquire Corstasis, which developed and is commercia.
